1 |
|
Machine Learning in Drug Discovery |
Graduate Lecture - Thursday 3rd June 2021, with Dr Fergus Boyles. Department of Statistics, University of Oxford. |
Fergus Boyles |
23 Jun 2021 |
2 |
|
Why we work on Alzheimer’s disease |
Housed within the Target Discovery Institute, the Alzheimer’s Research UK Oxford Drug Discovery Institute (ODDI) juxtaposes drug discovery expertise alongside scientific and academic understanding of patients, disease mechanisms and model systems. |
John Davis |
30 Nov 2016 |
3 |
Creative Commons |
Why we work on Alzheimer’s disease |
Housed within the Target Discovery Institute, the Alzheimer’s Research UK Oxford Drug Discovery Institute (ODDI) juxtaposes drug discovery expertise alongside scientific and academic understanding of patients, disease mechanisms and model systems. |
John Davis |
30 Nov 2016 |
4 |
Creative Commons |
X-rays for drug discovery |
Professor Frank von Delft works to ensure that X-ray structures can serve as a routine and predictive tool for generating novel chemistry for targeting proteins. |
Frank von Delft |
23 Sep 2016 |
5 |
Creative Commons |
X-rays for drug discovery |
Professor Frank von Delft works to ensure that X-ray structures can serve as a routine and predictive tool for generating novel chemistry for targeting proteins. |
Frank von Delft |
23 Sep 2016 |
6 |
|
Targeting drug discovery |
The development of new medicines is dependent on the identification of novel drug targets. |
Kilian Huber |
28 Apr 2016 |
7 |
Creative Commons |
Targeting drug discovery |
The development of new medicines is dependent on the identification of novel drug targets. |
Kilian Huber |
28 Apr 2016 |
8 |
|
X-rays for drug discovery |
Dr Frank von Delft works to ensure that X-ray structures can serve as a routine and predictive tool for generating novel chemistry for targeting proteins. |
Frank von Delft |
28 Apr 2016 |
9 |
Creative Commons |
Chemistry, epigenetics and drugs |
Alteration of gene expression is fundamental to many diseases. A better understanding of how epigenetic proteins affect diseases provides a starting point for therapy development and the discovery of new drug. |
Paul Brennan |
28 Jul 2015 |
10 |
Creative Commons |
Chemistry, epigenetics and drugs |
Alteration of gene expression is fundamental to many diseases. A better understanding of how epigenetic proteins affect diseases provides a starting point for therapy development and the discovery of new drug. |
Paul Brennan |
28 Jul 2015 |
11 |
Creative Commons |
Why do we need to reconstruct drug discovery? |
Dr Javier Lezaun and Professor Chas Bountra give a talk about drug discovery. |
Chas Bountra, Javier Lezaun |
17 Feb 2015 |
12 |
|
Artemisinin therapy for malaria |
Professor Nick White talks about the future of artemisinin and other drug therapies for malaria. |
Nick White |
16 Dec 2014 |
13 |
|
New frontiers in stem cell neuroscience and drug discovery |
NDCN Seminar |
Zameel Cader |
16 Dec 2014 |
14 |
|
Synthesizing Anti-Cancer Drugs from Nature |
Chemicals found in nature can have incredibly useful functionality, including anti-malarial and anti-cancer properties. However, they are usually found in small amounts. |
Chris Jones |
19 Jul 2013 |
15 |
Creative Commons |
Drug Discovery: Your questions |
How does medicine work? How are new drugs made? What role does the pharmaceutical industry play? Professors Stefan Knapp and Chas Bountra joined Science Oxford Live in spring 2013 for an evening of Scientists on the sofa, to take your questions. |
Stefan Knapp, Chas Bountra |
16 Jul 2013 |
16 |
Creative Commons |
Drug Discovery |
How does medicine work? How are new drugs made? What role does the pharmaceutical industry play? Professors Stefan Knapp and Chas Bountra work in the field of drug discovery. They joined Science Oxford talks in spring 2013. |
Chas Bountra |
16 Jul 2013 |
17 |
Creative Commons |
Discovery of new medicines and the future of drug development |
How does medicine work? How are new drugs made? What role does the pharmaceutical industry play? Professors Stefan Knapp and Chas Bountra work in the field of drug discovery. They joined Science Oxford talks in spring 2013. |
Stefan Knapp |
16 Jul 2013 |
18 |
Creative Commons |
Artemisinin therapy for malaria by Professor Nick White |
Professor Nick White talks about the future of artemisinin and other drug therapies for malaria. |
Nick White |
18 Jun 2013 |
19 |
Creative Commons |
Artemisinin therapy for malaria by Professor Nick White |
Professor Nick White talks about the future of artemisinin and other drug therapies for malaria. |
Nick White |
18 Jun 2013 |
20 |
Creative Commons |
Development of chemical probes |
Professor Stefan Knapp tells us how the development of chemical probes helps us to find new drugs. |
Stefan Knapp |
21 May 2013 |
21 |
Creative Commons |
Development of chemical probes |
Professor Stefan Knapp tells us how the development of chemical probes helps us to find new drugs. |
Stefan Knapp |
21 May 2013 |
22 |
Creative Commons |
Membrane proteins and drug development |
Dr Liz Carpenter talks about her research on membrane proteins and drug development. |
Liz Carpenter |
29 Apr 2013 |
23 |
Creative Commons |
Membrane proteins and drug development |
Dr Liz Carpenter talks about her research on membrane proteins and drug development. |
Liz Carpenter |
29 Apr 2013 |
24 |
|
Molecular immunology |
Dr Christian Eggeling tells us how new imaging methods help us understand immunology at the molecular level. |
Christian Eggeling |
29 Apr 2013 |
25 |
|
Molecular immunology |
Dr Christian Eggeling tells us how new imaging methods help us understand immunology at the molecular level. |
Christian Eggeling |
29 Apr 2013 |
26 |
Creative Commons |
Drug Discovery |
Professor Chas Bountra explains how new drugs can offer novel treatments for neurodegenerative and gastrointestinal diseases, as well as pain disorders. |
Chas Bountra |
20 Dec 2010 |
27 |
Creative Commons |
Drug Discovery |
Professor Chas Bountra explains how new drugs can offer novel treatments for neurodegenerative and gastrointestinal diseases, as well as pain disorders. |
Chas Bountra |
20 Dec 2010 |